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Thermal analysis of N-carbamoyl benzotriazole derivatives
Thermal properties of N-carbamoyl benzotriazole deriva-
tives and N,N’,N’’-tribenzyloxyisocyanuric acid were in-
vestigated using thermogravimetric analysis and diﬀ eren-
tial scanning calorimetry. The results revealed a diﬀ erence 
between structural analogs of N-carbamoyl benzotriazole 
derivatives. They seem to be in agreement with the previ-
ously proposed formation of N,N’,N’’-tribenzyloxyisocyan-
uric acid from 1-(N-benzyloxycarbamoyl) benzotriazole, via 
an intermediary N-benzyloxyisocyanate acid, during heat-
ing. Substantially diﬀ erent thermal properties were ob-
served for structural analogues, 1-(N-methoxycarbamoyl) 
benzotriazole and 1-(N-ethoxycarbamoyl) benzotriazole. In 
contrast to N-benzyloxyisocyanate, no corresponding reac-
tions were observed for their decomposition products, i.e., 
methoxyisocyanate and ethoxyisocyanate.
Keywords: N-carbamoyl benzotriazole, N,N’,N’’-tribenzyl-
oxyisocyanuric acid, thermogravimetric analysis, diﬀ eren-
tial scanning calorimetry, ATR-FTIR
Hydroxyurea and its derivatives show versatile biological activities. Today, they are 
employed in the treatment of various neoplastic and non-neoplastic diseases such as vari-
ous types of cancer (1, 2), sickle cell anemia (3), HIV infection (4, 5), t hrombocythemia (6) 
and psoriasis (7). N-substituted benzotriazoles are well known as useful synthons in the 
synthesis of carbamates, ureas, semicarbazides and carbazides (8, 9). Recent reports on 
1-(N-benzyloxycarbamoyl) benzotriazole revealed its crystal structure (10) and usage in 
the synthesis of hydroxyurea derivatives (11, 12). Butula and Jadrĳ ević-Mladar Takač (11) 
reported the preparation of N,N’,N’’-tribenzyloxyisocyanuric acid from 1-(N-benzyloxy-
carbamoyl) benzotriazole a er its thermal decomposition in the presence of a catalytic 
amount of imidazole, via N-benzyloxyisocyanate as an intermediary product. In the cur-
rent paper, we explore thermal decomposition of 1-(N-benzyloxycarbamoyl) benzotriazole, 
its structural analogues 1-(N-methoxycarbamoyl) benzotriazole and 1-(N-ethoxycarbamo-
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(all structures are given in Fig. 1). These compounds were recently proven to be cytotoxic 
agents against monocytic THP-1 cell lines, whereas N,N’,N’’-tribenzyloxyisocyanuric acid 
exerted antimicrobial activity against E. coli strains (12).
EXPERIMENTAL
1-(N-benzyloxycarbamoyl) benzotriazole (1), 1-(N-methoxycarbamoyl) benzotriazole 
(2), 1-(N-ethoxycarbamoyl) benzotriazole (3) and N,N’,N’’-tribenzyloxyisocyanuric acid (4) 
were synthesized according to previously published procedures (11, 12).
Methods
Thermogravimetric analysis (TGA). – Thermogravimetric (TG) experiments were carried 
out using a Perkin Elmer (USA) Pyris 1 TGA thermogravimetric analyzer. Analysis was 
performed in an open aluminum pan with samples weighing approximately 5 mg. All 
samples were measured at 30 to 500 °C at the heating rate of 10 °C min–1 under a continuous 
nitrogen ﬂ ow at a rate of 30 mL min–1.
A enuated total reﬂ ectance infrared spectroscopy (ATR-IR). – The samples were addition-
ally analyzed using spectroscopy using a Perkin Elmer (USA) Spectrum 100 FT-IR spec-
trometer. For each sam ple, 4 scans at a resolution of 4 cm–1 were recorded between 4000 
cm–1 and 450 cm–1.
Diﬀ erential scanning calorimetry (DSC). – DSC thermograms of solid products were re-
corded on a Perkin Elmer (USA) DSC 7 diﬀ erential scanning calorimeter. The instrument 
was calibrated with indium and zinc prior to the analysis of samples under dry nitrogen 
purge at a ﬂ ow rate of 35 mL min–1. All samples (≈ 5 mg) were accurately weighed on a 
Me ler Toledo (Switzerland) MB microbalance, placed in a sealed aluminum pan with a 
pierced lid and scanned at a heating rate of 10 °C min–1 over the temperature range of 20 
to 500 °C. An empty sealed aluminum pan with a pierced lid was used as a reference.
RESULTS AND DISCUSSION
Thermogravimetric analysis 
Compound 1 evaporated in two steps, the ﬁ rst step taking place between 166 and 
265 °C with the maximum rate at 232 °C (66 % loss of mass), and the second step between 
Fig. 1. Structures of 1-(N-benzyloxycarbamoyl) benzotriazole (1), 1-(N-methoxycarbamoyl) benzotri-
azole (2), 1-(N-ethoxycarbamoyl) benzotriazole (3) and N,N’,N’’-tribenzyloxyisocyanuric acid (4).
209
I. Kos et al.: Thermal analysis of N-carbamoyl benzotriazole derivatives, Acta Pharm. 65 (2015) 207–213.
 
265 and 328 °C with the maximum rate at 305 °C (98.4 % loss of mass), remaining further 
stable up to 500 °C. Compound 2 evaporated between 96 and 193 °C with the maximum 
rate at 180 °C, while compound 3 evaporated between 99 and 209 °C with the maximum 
rate at 200 °C. Isocyanuric acid derivative (4) lost 98 % of mass in a single step from 247 to 
343 °C with the maximum rate at 288 °C and the remaining 2 % was stable up to 500 °C. 
TGA measurements for all compounds are given in Fig. 2. Section A in Fig. 2 denotes the 
temperature region corresponding to the second evaporation step of compound 1 and 
evaporation of compound 4, indicating transition from 1 to 4 during the heating process.
TGA revealed a diﬀ erence between structural analogs of N-carbamoyl benzotriazole 
derivatives. Compounds 2, 3 and 4 evaporated in a single step, while compound 1 evapo-
rated in two steps. The second step of evaporation of compound 1 was found with almost 
the same interval as the interval of evaporation of compound 4, thus conﬁ rming a possible 
cyclization reaction taking place during the heating process, as suggested by Butula and 
Jadrĳ ević-Mladar Takač (11). They reported the formation of compound 4 when compound 
1 was heated at 120–130 °C in the presence of a catalytic amount of imidazole, and noted 
an exothermic reaction accompanied by an increase of reaction mixture temperature up to 
150 °C.
Diﬀ erential scanning calorimetry 
Compound 1 showed a sharp endothermic peak at 122 °C (region 1a in Fig. 3a, dH = 
108 J g–1), and another exothermic process between 168 and 250 °C, characterized by a 
broad peak with the maximum at 235 °C (region 1b in Fig. 3a, dH = –233 J g–1). Additional 
ﬂ uctuations in heat ﬂ ow were observed from 250 to 330 °C (region 1c in Fig. 3a). Compound 
4, a suggested cyclization product of 1, showed a sharp endothermic peak at 249 °C (region 
Fig. 2. TGA of 1-(N-benzyloxycarbamoyl) benzotriazole (1), 1-(N-methoxycarbamoyl) benzotriazole 
(2), 1-(N-ethoxycarbamoyl) benzotriazole (3) and N,N’,N’’-tribenzyloxyisocynauric acid (4).
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4a in Fig. 3a, dH = 114 J g–1), and a two-step exothermic process between 255 and 350 °C, 
with a peak maximum at 298 °C (regions 4b and 4c in Fig. 3a, dH = –889 J g–1).
Compound 2 showed a sharp endothermic peak at 145 °C (region 2a in Fig. 3b, dH = 
159 J g–1), followed by a two-step endothermic process between 149 and 257 °C (regions 2b 
and 2c in Fig. 3b, dH = 355 J g–1). Similar behavior was exerted by compound 3, with a sharp 
endothermic peak at 119 °C (region 3a in Fig. 3b, dH = 121 J g–1), and an endothermic process 
between 129 and 247 °C (regions 3b and 3c in Fig. 3b, dH = 275 J g–1).
DSC analysis of compound 1 showed a broad exothermic peak between 168 and 250 °C, 
which is in excellent agreement with the ﬁ rst step of its thermal decomposition (region A 
Fig. 3. DSC thermograms of: a) 1-(N-benzyloxycarbamoyl) benzotriazole (1) and N,N’,N’’-triben-
ziloxyisocyanuric acid (4); b) 1-(N-methoxycarbamoyl) benzotriazole (2) and 1-(N-ethoxycarbamoyl) 
benzotriazole (3).
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in Fig. 4). Benzotriazole (BtH), a side-product of this decomposition, evaporated between 
127 and 194 °C, followed by exothermal decomposition between 306 and 410 °C (13). This 
region corresponds roughly to the region of endothermic decomposition of compound 4 
(255 to 350 °C, regions 4b and 4c, Fig. 3a), which may at least in part account for the complex 
features of DSC thermograms of compound 1 in this range (region B in Fig. 4). TGA curve 
of compound 4 corresponds to this range of temperatures as well (region A in Fig. 2).
When comparing the TGA or DSC data of compounds 2 and 3, similar endothermic 
decomposition processes can be observed (regions 2b and 2c, and 3b and 3c in Fig. 3b). 
Further fate of the products, i.e. methoxyisocyanate and ethoxyisocyanate, is quite diﬀ er-
ent from that of benzyloxyisocyanate, a decomposition product of compound 1. Probably, 
it readily trimerizes to form compound 4 via an intermediary, N-benzyloxyisocyanate (11), 
according to the scheme given in Fig. 5.
Fig. 4. TGA and DSC proﬁ les of 1-(N-benzyloxycarbamoyl) benzotriazole (1).
Fig. 5. The proposed scheme for the decomposition of 1-(N-benzyloxycarbamoyl) benzotriazole (1).
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IR spectra
To support the proposed reaction scheme explaining the processes taking place dur-
ing the DSC measurements of compound 1, we measured the IR spectrum of the interme-
diate obtained by heating compound 1 to 250 °C. The obtained spectrum corresponds re-
markably well to the spectrum of compound 4 obtained at 290 °C (Fig. 6), thus conﬁ rming 
the proposed formation of N,N’,N’’-tribenzyloxyisocynauric acid during heating of 1-(N-
benzyloxycarbamoyl) benzotriazole. Additional conﬁ rmation is the presence of peaks at 
1740, 1402, 1197, 1001 and 905 cm–1, characteristic for N,N’,N’’-tribenzyloxyisocynauric acid 
(11, 12).
CONCLUSIONS
All four compounds melted endothermically, with peaks at 122, 145, 119 and 249 °C 
for compounds 1, 2, 3, and 4, respectively. These ﬁ ndings are in good agreement with the 
previously reported melting points (15, 18). Melting is not accompanied by decomposition, 
as conﬁ rmed by TGA data. In adition, the results of TGA and DSC analyses seem to be in 
agreement with the previously proposed formation of N,N’,N’’-tribenzyloxyisocynauric 
Fig. 6. IR spectra of the intermediate obtained by heating 1-(N-benzyloxycarbamoyl) benzotriazole (1) 
to 250 °C (top) and by heating N,N’,N’’-tribenzyloxyisocyanuric acid (4) to 290 °C (bo om).
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acid during the heating process of 1-(N-benzyloxycarbamoyl) benzotriazole. In contrast to 
N-benzyloxyisocyanate, no corresponding reactions were observed for methoxyisocya-
nate and ethoxyisocyanate, i.e., the decomposition products of the structural analogues 
1-(N-methoxycarbamoyl) benzotriazole and 1-(N-ethoxycarbamoyl) benzotriazole. Find-
ings described in this work could be useful in the preparation of new and modiﬁ cation of 
the existing compounds, particularly in the light of the recently conﬁ rmed biological ef-
fects of these compounds (11, 12).
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